Can I Take Lion's Mane with Egrifta (Tesamorelin)?
HealthRX.com
No documented interaction, but the pair has never been tested
Key numbers
- 1.4 mgEgrifta SV dose: once-daily subcutaneous injection in the abdomen for HIV-associated lipodystrophySource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 5%Tesamorelin patients who developed HbA1c of 6.5% or higher by week 26, vs 1% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 47%Share of tesamorelin patients with IGF-1 above 2 SDS after 26 weeks of treatmentSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 3 g a dayMushroom powder dose used in a 16-week trial in adults with mild cognitive impairmentSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 1.8 gSingle lion's mane dose in a 41-person pilot of healthy adults, tested for attentionSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
At a glance
- Tesamorelin / Egrifta SV, 1.4 mg subcutaneously once daily for HIV-associated lipodystrophy [2]
- Lion's mane / edible mushroom (Hericium erinaceus) sold as a dietary supplement; no FDA-approved drug application [4]
- Egrifta SV label interactions / CYP450-metabolized drugs and glucocorticoids; lion's mane is not named [2]
- Glucose / HbA1c of 6.5% or higher in 5% on tesamorelin vs 1% on placebo by week 26 [2]
- IGF-1 / raised by tesamorelin; 47% above 2 SDS at 26 weeks, monitored per the label [2]
- Lion's mane growth-factor data / nerve growth factor, from cell and mouse work [5]
- Lion's mane human evidence / small trials of cognition and mood, not glucose or IGF-1 [3][1]
What Egrifta SV does
Tesamorelin is a synthetic analogue of human growth hormone-releasing factor (GHRH), the hypothalamic peptide that tells the pituitary to make and release growth hormone. It binds and stimulates GRF receptors on pituitary somatotroph cells with potency similar to the body's own GRF, and the resulting growth hormone raises IGF-1 and IGFBP-3 [2]. It is a peptide, not growth hormone itself [2].
FDA approved Egrifta for one use: reducing excess abdominal (visceral) fat in HIV-infected adults with lipodystrophy [2]. The label states that long-term cardiovascular safety has not been established, that the drug is not indicated for weight loss because its effect on weight is neutral, and that there are no data showing it improves adherence to antiretroviral therapy [2].
The Egrifta SV label says the dose is 1.4 mg (0.35 mL of the reconstituted solution) injected under the skin of the abdomen once daily, rotating sites and avoiding scar tissue, bruises and the navel [2]. Egrifta WR is a separate formulation at 1.28 mg with different reconstitution and storage, and the labels state the two are not substitutable [6].
What lion's mane is and what has been tested
Lion's mane (Hericium erinaceus) is an edible mushroom sold over the counter as a dietary supplement. A Drugs@FDA search for hericium returns no approved drug application [4]. The human evidence is a handful of small trials, so no health claim is established.
In a double-blind trial of 30 adults aged 50 to 80 with mild cognitive impairment, about 3 g a day of mushroom powder for 16 weeks produced higher scores on a dementia rating scale than placebo at weeks 8, 12 and 16; scores fell significantly in the 4 weeks after people stopped taking it, and laboratory tests showed no adverse effect [3]. A 12-week trial of a fruiting-body supplement improved only the MMSE; the other two cognitive tests are not reported as improved [7]. A 4-week cookie trial in 30 women found depression and complaint scores lower than the group's own baseline, with between-group differences in only two complaint items [8]. A 41-person pilot in healthy adults found faster performance on one attention task 60 minutes after a 1.8 g dose (p=0.005) and a trend toward lower subjective stress at 28 days (p=0.051), with other results null [1].
No systematic human safety assessment, dose-finding study or adverse-event database for lion's mane was found.
Is there a known interaction between lion's mane and tesamorelin?
The Egrifta SV drug interactions section addresses two categories. The first is drugs metabolized by CYP450 liver enzymes: the label notes that published data suggest growth hormone can change CYP450-mediated clearance, names corticosteroids, sex steroids, anticonvulsants and cyclosporine as examples, and says to monitor patients taking such drugs [2]. The second is glucocorticoid replacement: growth hormone inhibits 11-beta-HSD1, the enzyme that converts cortisone and prednisone to their active forms, so people on replacement therapy for hypoadrenalism may need higher maintenance or stress doses after starting tesamorelin [2]. Lion's mane is not named in either category [2].
The label's measured effects on other drugs have been small. In healthy subjects tesamorelin changed simvastatin exposure by about 8% (simvastatin acid about 15%) and ritonavir exposure by about 9%, which the label treats as no significant impact [2].
No human study of lion's mane with any prescription medicine, including blood thinners, diabetes drugs or antidepressants, was found in PubMed. That means the interaction risk is unknown, not that interactions are impossible.
Questions worth asking
Glucose: the lab that matters most here
Tesamorelin raises growth hormone, and the label warns it can cause glucose intolerance or diabetes. HbA1c of 6.5% or higher developed in 5% of tesamorelin patients versus 1% on placebo by week 26, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6) [2]. The label directs prescribers to evaluate glucose status before starting, to monitor treated patients periodically, and to monitor patients with diabetes at regular intervals for potential development or worsening of retinopathy [2].
The lion's mane trials above report cognitive scores and mood questionnaires, not glucose control [3][1][8]. What exists is animal work: in rats with streptozotocin-induced diabetes, 28 days of an aqueous H. erinaceus extract lowered serum glucose and raised serum insulin [9]. That is a rat model with a different preparation from a commercial capsule, and it does not establish what the mushroom does to blood sugar in a person taking tesamorelin.
Growth factors: IGF-1 versus NGF
Egrifta SV raises IGF-1 [2]. The label says the effects of prolonged IGF-1 elevation are unknown and that levels should be monitored during therapy, with discontinuation considered if they stay high (for example above 3 SDS), especially when fat loss is not robust [2]. Among patients treated for 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS; among those treated for 52 weeks, 34% and 23% [2].
Lion's mane's growth-factor findings are preclinical. An H. erinaceus extract promoted nerve growth factor (NGF) gene expression and NGF protein secretion in human astrocytoma cells, and mice fed 5% mushroom powder for 7 days had higher NGF mRNA in the hippocampus [5]. The human trials measured test scores and mood, not NGF [3][1].
What the Egrifta SV label lists
The most commonly reported reactions, above 5%, are arthralgia, injection site redness, injection site itching, pain in an extremity, peripheral edema and myalgia; in the label's table arthralgia was 13% versus 11% on placebo, peripheral edema 6% versus 2% and myalgia 6% versus 2% [2]. Injection site reactions occurred in 25% of tesamorelin patients versus 14% on placebo during the first 26 weeks, and hypersensitivity reactions in 4% (itching, redness, flushing, hives, rash), for which the label advises patients to seek prompt medical attention and stop treatment [2]. Fluid retention can include edema, joint pain and carpal tunnel syndrome [2].
Tesamorelin is contraindicated in active malignancy, in disruption of the hypothalamic-pituitary axis, in known hypersensitivity to tesamorelin or its excipients, and in pregnancy; the label says any preexisting malignancy should be inactive with treatment complete before starting [2]. For lion's mane, the cancer-related findings come from cell and mouse experiments [10].
Doses used in the lion's mane trials
The studied amounts were about 3 g a day of mushroom powder for 16 weeks in the mild cognitive impairment trial, a single 1.8 g dose and 28 days of 1.8 g in the healthy-adult pilot, and mushroom cookies for 4 weeks in the 30-woman trial [3][1][8]. These are study doses, not recommended doses.
Frequently asked questions
What does the Egrifta SV label list as drug interactions?
Does lion's mane raise IGF-1?
Does lion's mane lower blood sugar?
What labs does the Egrifta SV label say to track?
How much lion's mane was used in the human trials?
References
Show all 10 referencesHide references
- Docherty S, Doughty FL, Smith EF. The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study. Nutrients. 2023;15(22).
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009;23(3):367-72.
- Drugs@FDA: FDA-Approved Drugs.
- Mori K, Obara Y, Hirota M, Azumi Y, Kinugasa S, Inatomi S, et al. Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. Biol Pharm Bull. 2008;31(9):1727-32.
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K. Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomed Res. 2019;40(4):125-131.
- Nagano M, Shimizu K, Kondo R, Hayashi C, Sato D, Kitagawa K, et al. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed Res. 2010;31(4):231-7.
- Liang B, Guo Z, Xie F, Zhao A. Antihyperglycemic and antihyperlipidemic activities of aqueous extract of Hericium erinaceus in experimental diabetic rats. BMC Complement Altern Med. 2013;13:253.
- Kim SP, Nam SH, Friedman M. Hericium erinaceus (Lion's Mane) mushroom extracts inhibit metastasis of cancer cells to the lung in CT-26 colon cancer-tansplanted mice. J Agric Food Chem. 2013;61(20):4898-904.